Drug class | Drug | Dose | Study (phase) | Study timec | Population | N | Age criteria | Agea | Background | Primary outcome/endpoint | Main conclusion |
---|---|---|---|---|---|---|---|---|---|---|---|
CD80/86 inhibitor | abatacept | 10 mg/kg q4w | dIM101–033, NCT00095173 | 26 | PJIA, SJIA (without systemic features), extended OJIA | 190 | 6 to 17 | 12.4 | MTX, corticosteroids | Disease flare | Effective |
IL-1 inhibitor | anakinra | 1 mg/kg/d | 16 | PJIA | 86 | 2 to 17 | 12 | MTX | Safety | Efficacy is inconclusive | |
2 mg/kg/d | ANAJIS, NCT00339157 | 4.33 | SJIA | 24 | 2 to 20 | 8.5 | NSAID, corticosteroids | Modified ACR Pedi 30 | Effective | ||
canakinumab | 4 mg/kg single dose | 4.33 | SJIA | 84 | 2 to 19 | 8a | MTX, NSAID, corticosteroids | ACR Pedi 30 | Effective | ||
4 mg/kg q4w | 120 | SJIA | 177 | 2 to 19 | 8a | MTX, NSAID, corticosteroids | Disease flare | Effective | |||
rilonacept | 2.2 mg/kg qw | RAPPORT, NCT00534495 | 24 | SJIA | 71 | 1 to 19 | 10 | NA | Modified ACR Pedi 30 | Effective | |
2.2 mg/kg qw, 4.4 mg/kg qw | IL1T-AI-0504, NCT01803321 (II) [60] | 104 | SJIA | 24 | 4 to 20 | 12.6 | MTX, NSAID, corticosteroids | ACR Pedi 30 | Not effective | ||
IL-6 inhibitor | tocilizumab | 8 mg/kg q4w, 10 mg/kg q4w | hCHERISH, NCT00988221 | 104 | PJIA, extended OJIA | 188 | 2 to 17 | 11 | MTX, corticosteroids | Disease flare | Effective |
8 mg/kg q2w, 12 mg/kg q2w | iTENDER, NCT00642460 | 260 | SJIA | 112 | 2 to 17 | 9.7 | MTX, corticosteroids | Modified ACR Pedi 30 | Effective | ||
8 mg/kg q2w | MRA316JP, NCT00144599 (III) [68]b | 18 | SJIA | 56 | 2 to 19 | 8.3 | corticosteroids | ACR Pedi 30 | Effective | ||
TNF inhibitor | adalimumab | 24 mg/m2 q2w | jM11–328, NCT01166282 | 12 | ERA | 46 | 6 to 17 | 12.9 | MTX or SSZ, NSAID | Joints with active arthritis | Effective |
40 mg q2w | Horneff 2012, EudraCT 2007–003358-27(III) [72] | 12 | ERA | 32 | 12 to 17 | 15.3 | NSAID, corticosteroids | ASAS40 | Effective | ||
24 mg/m2 q2w | k,bDE038, NCT00048542 | 48 | PJIA | 171 | 4 to 17 | 11.2 | MTX, NSAID, corticosteroids | Disease flare | Effective | ||
20 mg q2w, 40 mg q2w | 78 | JIA-associated uveitis | 90 | 2 to 18 | 8.9 | MTX | Treatment failure | Effective | |||
24 mg/m2 q2w, 40 mg q2w | lADJUVITE, NCT01385826 (II/III) [77] | 52 | JIA-associated uveitis | 32 | > = 4 | 9.5a | MTX, corticosteroids (oral and topical) | LFP improvement > = 30% and no worsening on slit lamp | Effective | ||
etanercept | 0.8 mg/kg/qw | Horneff 2015, EudraCT 2010–020423-51 (III) [78] b | 48 | ERA | 38 | 6 to 17 | 13.3 | SSZ, NSAID, corticosteroids | Disease flare | Effective | |
0.8 mg/kg/qw | 30.33 | PJIA | 69 | 4 to 17 | NA | NSAID, corticosteroids | Disease flare | Effective | |||
0.8 mg/kg/qw | o20021616, NCT03780959 (II/III) [81]b | 30.33 | PJIA | 69 | 4 to 18 | 10.5 | NSAID | Disease flare | Effective | ||
0.8 mg/kg/qw | 20021628, NCT03781375 (III) [82] | 52 | PJIA | 25 | NA | 10.1 | MTX | ACR Pedi 30 | NA | ||
0.8 mg/kg/qw | TREAT, NCT00443430 | 52 | PJIA | 85 | 2 to 17 | 10.5 | MTX | Clinical inactive disease | Not effective | ||
0.8 mg/kg/qw, 1.6 mg/kg/qw | b20021631, NCT00078806 (III) [85] | 39 | SJIA | 19 | 2 to 18 | 9.1 | MTX, NSAID, corticosteroids | Disease flare | NA | ||
0.8 mg/kg/qw | 12 | PJIA,RF−; OJIA, JPsA | 94 | 2 to 16 | 8.8a | MTX | Unclear | Effective | |||
golimumab | 30 mg/m2 q4w | 48 | PJIA, SJIA (without systemic features), PsA | 154 | 2 to 17 | 11.1 | MTX, corticosteroids | Disease flare | Not effective | ||
infliximab | 3 mg/kg, 6 mg/kg | CR004774, NCT00036374 (III) [90] | 58 | PJIA | 122 | 4 to 17 | 11.2 | MTX, NSAID, corticosteroids | ACR Pedi 30 | Not effective | |
3–5 mg/kg | ACUTE-JIA, NCT01015547 (III) [91] | 54 | PJIA | 60 | 4 to 15 | 9.6 | MTX, other DMARDs | ACR Pedi 75 | Effective | ||
JAK inhibitor | tofacitinib | 2–5 mg BID | nA3921104, NCT02592434 (III) [92]b | 44 | ERA, PJIA, PsA | 225 | 2 to 17 | 13a | NA | Disease flare | Effective |